Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 733-742

  Daemen, Toos ^a   Riezebos Brilman, Annelies ^a   Regts, Joke ^a   Dontje, Bert ^a   Van Der Zee, Ate ^b   Wilschut, Jan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; VIRUS RNA; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENE CONSTRUCT; HIGH RISK POPULATION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MODEL; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANIMALS; CANCER VACCINES; CELL LINE; CRICETINAE; ENHANCER ELEMENTS (GENETICS); FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 7244240998     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002; 2:342-350.
2. McMurray HR, Nguyen D, Westbrook TF & McCance DJ. Biology of human papillomaviruses. International Journal of Experimental Pathology 2001; 82:15-33.
3. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM & Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002; 347:1645-1651.
4. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF & Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348:518-527.
5. Munger K, Scheffner M, Huibregtse JM & Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumor suppressor gene-products. Cancer Surveys 1992; 12:197-217.
6. Eiben GL, Da Silva DM, Fausch SC, Le Poole IC, Nishimura MI & Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunology 2003; 16:111-121.
7. Liljestrom P & Garoff H. A new generation of animal-cell expression vectors based on the Semliki Forest virus Replicon. Bio-Technology 1991; 9:1356-1361.
8. Berglund P, Sjoberg M, Garoff H, Atkins GJ, Sheahan BJ & Liljestrom P. Semliki Forest Virus expression system - production of conditionally infectious recombinant particles. Bio-Technology 1993; 11:916-920.
9. Huckriede A, Bungener L, Holtrop M, Idema J, Waarts B-L, Daemen T & Wilschut J. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: evidence for cross-priming. Vaccine 2004; 22:1104-1113.
10. Sjoberg EM, Suomalainen M & Garoff H. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology (NY) 1994; 12:1127-1131.
11. Daemen T, Regts J, Holtrop M & Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Therapy 2002; 9:85-94.
12. Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B & Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003; 21:1082-1088.
13. Colmenero P, Berglund P, Kambayashi T, Biberfeld P, Liljestrom P & Jondal M. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Therapy 2001; 8:1307-1314.
14. Morris-Downes MM, Phenix KV, Smyth J, Sheahan BJ, Lileqvist S, Mooney DA, Liljestrom P, Todd D & Atkins GJ. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 2001; 19:1978-1988.
15. van der Burg SH, Kwappenberg KMC, O'Neill T, Brandt RMP, Melief CJM, Hickling JK & Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001; 19:3652-3660.
16. Lin KY, Guarnieri FG, Staveley-O'Carroll KE, Levitsky HI, August JT, Pardoll DM & Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Research 1996; 56:21-26.
17. Smits PH, Smits HL, Jebbink MF & ter Schegget J. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA. Virology 1990; 176:158-165.
18. Rayner JO, Dryga SA & Kamrud KI. Alphavirus vectors and vaccination. Reviews in Medical Virology 2002; 12:279-296.
19. Fournier P, Zeng JY & Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. International Journal of Oncology 2003; 23:673-680.
20. Wang LL, Smith D, Bot S, Dellamary L, Bloom A & Bot A. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. Journal of Clinical Investigation 2002; 110:1175-1184.
21. Berglund P, Fleeton MN, Smerdou C & Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17:497-507.
22. Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, Elmishad AG, Kast WM & Smith LR. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Research 2001; 61:7861-7867.
23. Cheng WF, Hung CF, Hsu KF, Chai CY, He LM, Polo JM, Slater LA, Ling M & Wu TC. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Human Gene Therapy 2002; 13:553-568.
24. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA & Johnston RE. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. Journal of Virology 1997; 71:3031-3038.
25. Klimp AH, van der Vaart E, Lansink PO, Withoff S, de Vries EG, Scherphof GL, Wilschut J & Daemen T. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Therapy 2001; 8:300-307.
26. Withoff S, Glazenburg KL, van Veen ML, Kraak MMJ, Hospers GAP, Storkel S, De Vries EGE, Wilschut J & Daemen T. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines. Gene Therapy 2001; 8:1515-1523.
27. Roks AJ, Henning RH, Buikema H, Pinto YM, Kraak MJ, Tio RA, de Zeeuw D, Haisma HJ, Wilschut J & van Gilst WH. Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta. Gene Therapy 2002; 9:95-101.